August 27, 2012
•
Alzheimer's in the News
On Friday, August 24, Eli Lilly announced that their beta-amyloid immunotherapy (solanezumab) failed to meet its primary clinical endpoints for Alzheimer's...
August 23, 2012
•
News
Cure Alzheimer's Fund co-founder & chairman, Jeff Morby, and lead scientist, Rudy Tanzi, Ph.D., discussed current developments in Alzheimer's...
August 21, 2012
•
Social Activism
The David K. Johnson (DKJ) Foundation was created in 2000 in honor and memory of David and Susan Johnson of Reading, Mass., to promote awareness of and provide...
August 7, 2012
•
Alzheimer's in the News
After failed second clinical trial, Bapineuzumab studies are dropped for patients with mild to moderate Alzheimer’s disease, as the drug was ineffective...
July 26, 2012
•
Research Updates
Dr. Giuseppina Tesco of Tufts University School of Medicine has found that “a moderate-to-severe TBI, or head trauma, is one of the strongest...
July 25, 2012
•
News
A new study of an existing drug for immune disorders that may have positive effects for Alzheimer’s patients has attracted national attention lately....
July 24, 2012
•
News
It was announced yesterday that Bapineuzumab, the Abeta immunotherapy drug, failed to meet cognitive and functional goals in a late stage trial of Alzheimer...
July 18, 2012
•
News
Cure Alzheimer’s Fund is pleased to salute Massachusetts General Hospital for placing number 1 in the current issue of U.S. News and World Report’s...
